1. Home
  2. JLL vs INSM Comparison

JLL vs INSM Comparison

Compare JLL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jones Lang LaSalle Incorporated

JLL

Jones Lang LaSalle Incorporated

HOLD

Current Price

$292.10

Market Cap

16.8B

Sector

Finance

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$145.36

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JLL
INSM
Founded
1997
1988
Country
United States
United States
Employees
48000
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.8B
30.1B
IPO Year
1997
2000

Fundamental Metrics

Financial Performance
Metric
JLL
INSM
Price
$292.10
$145.36
Analyst Decision
Buy
Strong Buy
Analyst Count
7
24
Target Price
$363.17
$198.04
AVG Volume (30 Days)
425.7K
1.9M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
45.13
N/A
EPS
16.40
N/A
Revenue
$26,115,600,000.00
N/A
Revenue This Year
$7.70
$174.73
Revenue Next Year
$6.91
$65.13
P/E Ratio
$18.28
N/A
Revenue Growth
11.45
N/A
52 Week Low
$194.36
$60.40
52 Week High
$363.06
$212.75

Technical Indicators

Market Signals
Indicator
JLL
INSM
Relative Strength Index (RSI) 39.79 48.49
Support Level $279.24 $142.99
Resistance Level $309.79 $149.08
Average True Range (ATR) 9.46 5.27
MACD 0.74 1.07
Stochastic Oscillator 36.74 65.62

Price Performance

Historical Comparison
JLL
INSM

About JLL Jones Lang LaSalle Incorporated

Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: